Oakcliff Capital Partners’s Cardlytics CDLX Stock Holding History

Oakcliff Capital Partners’s Portfolio CDLX Stock Details CDLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-33,974	Closed	-$7.58M	–	10
2022 Q2	$7.58M	Buy	33,974 +3,500	+11%	+$1.17M	5.59%	7
2022 Q1	$16.8M	Hold	30,474	–	–	8.69%	7
2021 Q4	$20.1M	Buy	30,474 +3,329	+12%	+$2.54M	9.2%	6
2021 Q3	$22.8M	Buy	27,145 +3,500	+15%	+$3.55M	10.09%	5
2021 Q2	$30M	Hold	23,645	–	–	12.93%	3
2021 Q1	$25.9M	Sell	23,645 -3,345	-12%	-$4.42M	12.3%	3
2020 Q4	$38.5M	Sell	26,990 -6,295	-19%	-$6.71M	15.3%	3
2020 Q3	$23.5M	Hold	33,285	–	–	10.17%	5
2020 Q2	$23.3M	Hold	33,285	–	–	12.38%	4
2020 Q1	$11.6M	Buy	33,285 +5,179	+18%	+$3.67M	8.14%	7
2019 Q4	$17.7M	Hold	28,106	–	–	10.54%	6
2019 Q3	$9.42M	Buy	+28,106	New	+$9.01M	6.37%	8

Other funds holding CDLX

CIP

CAS Investment Partners Westport, Connecticut $1.88B AUM 2.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

ACM

Alua Capital Management New York $103M AUM 11.88% 1-Year Est. Return

KGAMU

KPS Global Asset Management (UK) London, United Kingdom $620M AUM 14.15% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

JCM

JS Capital Management New York $223M AUM 104.76% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Oakcliff Capital Partners's CDLX Position: Q3 2022 in Review

Oakcliff Capital Partners sold out of Cardlytics (CDLX) in Q3 2022, closing a stake of 33,974 shares — an estimated $7.58M sold.

Oakcliff Capital Partners first reported a position in CDLX in Q3 2019 and held it in 12 quarters. The position peaked at $38.5M in Q4 2020. 132 funds tracked by Wall St. Rank hold CDLX as of Q3 2022.

Oakcliff Capital Partners reported no remaining Cardlytics position as of Q3 2022 after selling out during the quarter.
Oakcliff Capital Partners sold 33,974 Cardlytics shares in Q3 2022, an estimated $7.58M.
Oakcliff Capital Partners first reported a position in Cardlytics in Q3 2019 and held it in 12 quarters.
Oakcliff Capital Partners's Cardlytics position peaked at $38.5M in Q4 2020.
132 funds tracked by Wall St. Rank held Cardlytics as of Q3 2022.

Based on Oakcliff Capital Partners's 13F filing for Q3 2022, filed 14 Nov 2022.